Index | Baseline level (95% CI) | 12-Months follow-up (95%CI) |
---|---|---|
TP, g/L | 77.83 ± 5.97 (76.94–78.69) | 77.82 ± 7.56 (76.70–78.92) |
ALB, g/L | 49.10 ± 4.38 (48.46–49.74) | 52.46 ± 32.27 (47.76–57.23) |
GLB, g/L | 28.73 ± 4.48 (28.06–29.36) | 27.71 ± 4.21*(27.07–28.31) |
A/G | 1.75 ± 0.31 (1.71–1.80) | 1.93 ± 1.36**(1.74–2.14) |
ALT, U/L | 50.75 ± 76.07 (39.83–62.13) | 25.32 ± 25.32**(21.69–29.11) |
AST, U/L | 47.53 ± 65.94 (38.00–57.34) | 26.25 ± 14.62**(24.18–28.46) |
ALP, U/L | 86.44 ± 32.42 (82.08–91.53) | 80.85 ± 27.03(77.23–85.11) |
ChE, U/L | 8540.39 ± 2189.15 (8221.87–8863.37) | 8898.41 ± 2102.60 (8584.14–9199.52) |
TBA, μmol/L | 20.49 ± 30.77 (16.09–25.11) | 15.71 ± 21.99*(12.61–19.05) |
TBIL, μmol/L | 9.05 ± 8.12 (7.85–10.23) | 8.45 ± 4.37(7.84–9.12) |
DBIL, μmol/L | 4.12 ± 5.82 (3.28–4.99) | 3.50 ± 1.87(3.25–3.79) |
IDBIL, μmol/L | 4.93 ± 4.37 (4.26–5.54) | 4.95 ± 3.42(4.46–5.46) |
γ-GT, U/L | 41.52 ± 41.73 (35.60–47.82) | 27.11 ± 25.18**(23.49–30.86) |
GPDA, U/L | 100.67 ± 27.49 (96.78–104.81) | 93.81 ± 21.52*(90.84–97.09) |
AFP, ng/mL | 7.63 ± 16.87 (5.20–10.13) | 3.93 ± 7.94**(2.78–5.11) |
HBsAg, IU/mL | 14,194.86 ± 24,143.84 (10,711.40–17,771.29) | 7521.35 ± 16,629.74**(5107.19–9982.06) |
anti-HBs, mIU/mL | 1.41 ± 9.62 (0.02–2.84) | 0.90 ± 4.22(0.29–1.53) |
anti-HBc, S/CO | 8.54 ± 1.25 (8.35–8.71) | 8.25 ± 1.25**(8.06–8.43) |
HBeAg, PEIU/mL | 304.51 ± 547.03 (227.74–387.92) | 151.52 ± 412.97*(92.54–213.59) |
anti-HBe, S/CO | 10.39 ± 17.32 (7.90–12.98) | 5.26 ± 12.46(3.49–7.14) |
HBV-DNA, IU/mL | 2.91E8 ± 8.31E8 (1.68E8-4.11E8) | 1.62E7 ± 8.25E7**(4.25E6-2.85E7) |
Tim3, pg/mL | 879.23 ± 646.15 (787.90–977.09) | 655.98 ± 399.33**(600.65–717.37) |
Inflammation grading | 1.61 ± 0.75 (1.50–1.72) | 1.38 ± 0.55**(1.30–1.46) |
Fibrosis stage | 1.31 ± 1.07 (1.16–1.47) | 1.34 ± 0.95 (1.20–1.48) |